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Abstract
We reported that adenosine A1 receptor (A1AR) knockout (KO) mice develop lethal status epilepticus after
experimental traumatic brain injury (TBI), which is not seen in wild-type (WT) mice. Studies in epilepsy,
multiple sclerosis, and neuro-oncology suggest enhanced neuro-inflammation and=or neuronal death in A1AR
KO. We hypothesized that A1AR deficiency exacerbates the microglial response and neuronal damage after TBI.
A1AR KO and WT littermates were subjected to mild controlled cortical impact (3m=sec; 0.5mm depth) to left
parietal cortex, an injury level below the acute seizure threshold in the KO. At 24 h or 7 days, mice were
sacrificed and serial sections prepared. Iba-1 immunostaining was used to quantify microglia at 7 days. To assess
neuronal injury, sections were stained with Fluoro-Jade C (FJC) at 24 h to evaluate neuronal death in the
hippocampus and cresyl violet staining at 7 days to analyze cortical lesion volumes. We also studied the effects
of adenosine receptor agonists and antagonists on 3H-thymidine uptake (proliferation index) by BV-2 cells
(immortalized mouse microglial). There was no neuronal death in CA1 or CA3 quantified by FJC. A1AR KO
mice exhibited enhanced microglial response; specifically, Iba-1þmicroglia were increased 20–50% more in
A1AR KO versus WT in ipsilateral cortex, CA3, and thalamus, and contralateral cortex, CA1, and thalamus
( p< 0.05). However, contusion and cortical volumes did not differ between KO and WT. Pharmacological
studies in cultured BV-2 cells indicated that A1AR activation inhibits microglial proliferation. A1AR activation is
an endogenous inhibitor of the microglial response to TBI, likely via inhibition of proliferation, and this may
represent a therapeutic avenue to modulate microglia after TBI.
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Introduction
We previously reported that adenosine A1 receptor(A1AR) knockout (KO) mice develop lethal status epi-
lepticus after experimental traumatic brain injury (TBI), a
finding not seen in wild-type (WT) mice (Kochanek et al.,
2006). This finding was consistent with the known propensity
for post-traumatic seizures after experimental TBI (Golarai
et al., 2001) and the purported crucial role of A1AR in keeping
an epileptic focus localized (Fedele et al., 2006). Rapid mor-
tality in these mice, however, precluded the ability to study
appropriately the neuropathological consequences of this
injury.
The role of A1AR in the evolution of neuronal death, as
studiedwith A1AR agonists and antagonists, is complex. After
inducing TBI by controlled cortical impact (CCI) in mice,
Varma and associates (2002) reported that local injection of the
highly selective A1AR agonist 2-chloro-N-cyclopentyladeno-
sine (CCPA) attenuated neuronal loss in CA3, but not CA1.
Neither the A1AR agonist CCPA nor the highly selective A1
AR antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX),
however, affected cortical lesion volume. Use of A1AR KO
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mice in other brain injury models has yielded conflicting re-
sults. Olsson and associates (2004) reported that deletion of the
A1AR did not alter neuronal damage in a mouse model of
global cerebral ischemia, despite the fact that administration of
an A1AR antagonist, 8-cyclopentyltheophylline, in naı¨ve WT
mice, exacerbated the damage. In contrast, Fedele and col-
leagues (2006) reported marked exacerbation of neuronal
damage after kainic acid-induced status epilepticus in A1AR
KO versus WT mice.
Adenosine is not only an inhibitory neuromodulator, but
also an immunomodulator in the brain (reviewed in Dare´
et al., 2007). Newby (1984) described adenosine as a ‘‘retalia-
tory metabolite’’ that is released in response to injury and
affects immune function so as to protect against excessive
inflammation. Adenosine, through effects at A1, A2A, and A3
receptors, can have immunomodulatory effects on microglial
proliferation and function in culture (Hammarberg et al.,
2003; Si et al., 1996). Si and associates (1996) reported that non-
selective and selective A1AR agonists, but not A2AR agonists,
attenuated proliferation of rat microglia stimulated by phor-
bol. Recent studies using A1AR KO mice in experimental
allergic encephalitis (EAE) and neuro-oncology models sug-
gested substantively enhanced neuroinflammation in the KO
(Tsutsui et al., 2004). Specifically, A1AR KO mice showed
increased proinflammatory gene expression, demyelination,
and microglial proliferation versus WT. Enhanced microglial
proliferation and enhanced tumor growth were also observed
in A1AR KO mice versus WT after implantation of experi-
mental glioblastoma cells (Synowitz et al., 2006).
We hypothesized that A1AR deficiency would exacerbate
neuronal damage and the microglial response after experi-
mental TBI in mice. To test this hypothesis, we reduced the
injury level in the CCI model to a threshold below the acute
seizure threshold in A1AR KO mice, and studied neuropa-
thology and Iba-1 immunostaining after the injury. To further
explore the role of A1AR in regulating microglial prolifera-
tion, we studied the effect of A1AR agonists and antagonists
on 3H-thymidine incorporation (an index of cell proliferation)
by cultured BV-2 cells (a widely used immortalized mouse
microglial cell line).
Methods
Animals
All experiments were approved by the Institutional Animal
Care and Use Committee of the University of Pittsburgh
(Pittsburgh, PA). A1ARKOmicewere generated as previously
described (Kochanek et al., 2006). Heterozygous pairs were
bred at our facility and generated homozygous WT, homo-
zygous KO, and heterozygous offspring. Genotypes were
determined using polymerase chain reaction (PCR) on tail
deoxyribonucleic acid (DNA). Polymerase chain reaction was
performed at cycling temperatures of 948C, 3min, 30 cycles of
948C, 588C, 728C each 1min, and 728C, 8min. Primer pairs for
genotyping were described previously by Sun and associates
(2001). Products were separated on 1% agarose gel with 0.5%
ethidium bromide and visualized under ultraviolet light.
CCI model
Mixed gender A1AR KO andWT littermate mice at 12 to 22
weeks of age were subjected to CCI as previously described
(Kochanek et al., 2006; Sinz et al., 1999) with important
modifications as described below. In brief, mice were an-
esthetized with 4% isoflurane in N2O=O2 (2:1) by nose cone
and placed in a stereotactic frame. Isoflurane was reduced to
2% after positioning. Brain temperature was continuously
monitored by amicroprobe inserted through a burr hole in the
left frontal cortex. Brain temperature and rectal temperature
were maintained at 37 0.58C. A 5mm craniotomy was
performed over the left parietal-temporal cortex and the
bone flap was removed. Because our standard injury level
in the model produced a high rate of lethal status epilepticus
in A1KO mice (Kochanek et al., 2006), the injury level
was reduced to a velocity of 3m=sec at a depth of 0.5mm.
Pilot studies revealed that this was the highest injury level
that was below the threshold for inducing acute seizures in
the A1AR KO mouse in our laboratory. The bone flap was
replaced and sealed with dental cement and the scalp was
sutured closed. Anesthesia was discontinued and the mice
were placed in an oxygen hood for 30min before being re-
turned to their cages. Identical protocols were performed on
both WT and KO mice. In addition, naı¨ve control A1AR KO
and WT mice were also studied to assess baseline im-
munostaining. In shams, surgery (including craniotomy),
anesthesia, and 7 day recovery were identical to injured mice
except that CCI was not performed.
Assessment of Iba-1 immunostaining
At 7 days after CCI, mice were anesthetized with 4% iso-
flurane in N2O=O2 (2:1) and transcardially perfused with
50mL heparinized saline and 50mL 10% buffered formalin.
Brains were removed and cryoprotected in 15% and 30% su-
crose and then frozen in liquid nitrogen. Brain sections
(10 mm)were taken through the lesion at the level of the dorsal
hippocampus (between 2.5 and 3.0mm from the occiput) to
quantify microglia. Sections were stained with Iba-1 antibody
(Wako Chemicals, Richmond, VA), a microglia-specific anti-
gen (Ito et al., 2001). In brief, sections were washed in 1PBST
for 15min, blocked with 5% normal goat serum in PBST for
1 h, and then incubated in IBA-1 antibody (1:250) overnight at
48C. After 3 PBST washes, sections were incubated for 1 h in
FITC conjugated goat-anti rabbit IgG secondary antibody
(1:500). A representative brain section from each mouse was
evaluated for Iba-1 staining in the CA1 and CA3 regions of the
hippocampus, peri-contusional cortex, and dorsal thalamus,
both ipsilateral and contralateral to the injury. Each brain
section was photographed at 200with an exposure time of
5.7 sec. The number of activated microglia in Iba-1-stained
sections was quantified by a blinded observer (MLH) using
Image-J (NIH, Bethesda, MD) with a size threshold of 100
pixels, a value previously determined to produce results most
consistent with manual cell counting.
Assessment of neuronal injury by Fluoro-Jade C
staining in CA1 and CA3 hippocampus
A separate group of mice were sacrificed at 24 h via trans-
cardial perfusion with 50mL of heparinized saline and 50mL
of 10% buffered formalin. Brains from these mice were re-
moved, dehydrated, and embedded in paraffin. 5 mm sections
were taken through the lesion at the level of the dorsal hip-
pocampus (between 2.30mm and 1.94mm from bregma)
and stained with Fluoro-Jade C (FJC, Chemicon, Temecula,
CA) as previously described (Fink et al., 2004) to probe for
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acute neuronal degeneration. All sections were assessed
qualitatively for FJC-positive neurons in CA1 and CA3 by
light microscopy using a Nikon Eclipse E600 (Tokyo, Japan).
Analysis of brain tissue volumes
At 7 days after CCI, mice were anesthetized with 4% iso-
flurane in N2O=O2 (2:1) and transcardially perfused with
50mL of heparinized saline and 50mL of 10% buffered for-
malin. Brains were removed and cryoprotected in 15% and
30% sucrose and then frozen in liquid nitrogen. Each brain
was sectioned in its entirety from caudal to rostral at intervals
of 0.5mm. Four 10 mm sections were obtained at each interval
and stained with cresyl violet for lesion volume analysis.
Sections were evaluated by a blinded observer (MLH), and
grossly intact tissue, quantified as cortical areas in each sec-
tion, was recorded using the MCID imaging system (MCID
Imaging Research, St. Catherines, CA). For each brain interval
a mean of all four sections was used to assess both the
hemisphere contralateral and ipsilateral to injury for hemi-
spheric and cortical areas. The mean of each interval was
summed and multiplied by the interval length (0.5mm) to
calculate a volume for each of the areas listed above. From
each of the calculated volumes a percent difference (contra-
lateral minus ipsilateral) was also derived. In addition, the
injured cortex was further assessed by taking an additional
measurement that excluded those areas containing tissue, but
with obvious loss of staining, and considered them part of the
lesion. The resultant volumes quantifying tissue with normal
staining intensity (reflecting even greater tissue loss in injured
cortex) were then calculated using the same method as de-
scribed above.
Effects of adenosine agonists and antagonists
on 3H-thymidine incorporation in cultured BV-2 cells
We employed BV-2 cells, a widely used immortalized
mouse microglial cell line. The BV-2 cell line was created from
murine primary microglial cultures by transformation with
the J2 retrovirus carrying a v-raf=v-myc oncogene (Blasi et al.,
1990). BV-2 cells were kindly provided by Dr. Martin Morn-
sard (University Hospital Zurich, Switzerland). BV-2 cells
were grown to subconfluence in DMEM medium in 24-well
culture plates. Before treatments, BV-2 cells were growth
arrested for 24 h by reducing the concentration of fetal calf
serum from 10% to 0.3%, and then proliferation was initiated
by treating growth-arrested cells for 20 h with DMEM me-
dium supplemented with fetal calf serum (FCS; 2.5%) and
containing or lacking the various treatments (Table 1) or their
vehicles. After 20 h of incubation, treatments were repeated
with freshly prepared solutions but supplemented with 3H-
thymidine (1 mCi=mL) for an additional 4 h. The experiments
were terminated by washing the cells twice with phosphate-
buffered saline (PBS) and twice with ice-cold trichloroacetic
acid (TCA, 10%). The precipitate was solubilized in 500 mL of
0.3NNaOH and 0.1% sodium dodecylsulfate after incubation
at 508C for 2 h. Aliquots from each culture well were added
to 10mL of scintillation fluid and were counted in a liquid
scintillation counter.
Quantitative real-time PCR of adenosine receptor
mRNA expression in cultured BV-2 cells
Total RNAwas isolated from subconfluent BV-2 cells using
Trizol reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. cDNA was synthesized using
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) as per the
manufacturer’s instructions. Real-time PCR assay was per-
formed with the primers (Table 2) by using SYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA) in the AB
7300 Real-time PCR System. The threshold cycle (Ct) for target
was subtracted from the Ct for b-actin to calculate DCt, and
relativemRNA levelswere expressed as 2DCt as recommended
by Varma and Cheng (2008).
Statistical analysis
Individual comparisons between A1ARKO andWT groups
were made using Student’s t test. Multiple comparisons be-
tween groups were made using one-way analysis of variance
and appropriate post-hoc tests, corrected for multiple com-
parisons. All values are presented as mean standard error.
Table 1. Adenosine Receptor Agonists and Antagonists Used in BV-2 Cells
Compound Abbreviation
Type of
pharmacological probe
Receptor
selectivity
2-chloro-N6-cyclopentyladenosine CCPA Agonist A1AR
2-p-(2-carboxyethyl)phenethylamino-50
-N-ethylcarboxamidoadenosine (aka CGS 21860)
CGS Agonist A2AAR
2-chloro-N6-(3-iodobenzyl)-adenosine-50
-N-methyluronamide
Cl-IB-MECA Agonist A3AR
50-(N-ethylcarboxamido)adenosine NECA Agonist Non-selective
2-chloroadenosine 2-CADO Agonist Non-selective
1,3-dipropyl-8-cyclopentylxanthine DPCPX Antagonist A1AR
7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-
[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (aka SCH 58261)
SCH Antagonist A2AAR
8-[4-[((4-cyanophenyl)carbamoylmethyl)oxy]phenyl]-
1,3-di(n-propyl)xanthine (aka MRS 1754)
MRS Antagonist A2BAR
N-(2-Methoxyphenyl)-N0-[2-(3-pyridinyl)-4-quinazolinyl]-
urea (aka VUF 5574)
VUF Antagonist A3AR
All compounds were obtained from Sigma-Aldrich (St. Louis, MO). Details for all agonists and antagonists, except VUF, can be found in
Jacobson and Knutsen (2001). For information on VUF, see van Muijlwijk-Koezen and colleagues (2000).
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Results
A total of 51A1AR KO and 35 WT littermate mice were
subjected to mild CCI. Shams (n¼ 3 per genotype) were also
studied. The mortality rate was 31.4% in the KO and 0% in
WT. No mice died in the acute post-injury period. Rather, the
mice of both genotypes appeared to recover normally from
anesthesia. Despite generally vigorous appearance, mortality
occurred over several days post-trauma, with some KO mice
dying in their cages between 1 and 7 days after injury. Body
weight did not differ between A1ARKO andWT (27.10 0.60
vs. 26.80 0.47 g, NS, respectively).
Iba-1 staining in A1AR KOwas significantly greater than in
WT in six of the eight brain regions examined including ip-
silateral CA3, cortex, and thalamus, and contralateral CA1,
cortex, and thalamus (all p< 0.05, Fig. 1). Even in those
Table 2. Primers Used for Quantitative Real-Time PCR Analysis of Adenosine
Receptor mRNA Levels in BV-2 Cells
Protein
Real-time PCR forward
primer sequence (50-30)
Real-time PCR reverse
primer sequence (50-30)
Base pair size
of amplicon (bp)
b-actin actcttccagccttccttc atctccttctgcatcctgtc 171
A1AR agaaccacctccacccttct tactctgggtggtggtcaca 227
A2AAR tcaacagcaacctgcagaac ggctgaagatggaactctg 186
A2BAR gcgaataaaagctgctgtcc cctggagtggtccatcagtt 186
A3AR gttccgtggtcagtttggat gcgcaaacaagaagagaacc 216
FIG. 1. Iba-1 positive cell counts per 200HPF across multiple brain regions at 7 days after experimental traumatic brain
injury. (A) CA1 hippocampus, adenosine A1-receptor (A1AR) knockout (KO) (=, n¼ 13; 8 male, 5 female) versus wild-type
(WT) (þ=þ, n¼ 8; 4 male, 4 female), (B) CA3 hippocampus, (C) cortex, (D) thalamus. Iba-1 staining identified activated
microglia in A1AR KO that was robust and significantly greater than in WT in six of the eight brain regions examined
including ipsilateral CA3, cortex, and thalamus, and contralateral CA1, cortex, and thalamus. Even in those regions not
reaching significance in A1AR KO versus WT, trends toward greater Iba-1 immunostaining were observed in A1AR KO.
*p< 0.05.
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regions not reaching significance in KO versus WT, trends
toward greater Iba-1 immunostaining were observed in KO
(Fig. 1). Representative examples of Iba-1 immunostaining in
A1AR KO and WT are shown in Figure 2A–D. TBI induced a
marked microglial response as reflected by the clear differ-
ence between respective sections from the hemispheres ip-
silateral and contralateral to injury and when compared to
naı¨ve animals. Iba-1 immunostaining in brain sections from
naı¨ve A1AR KO and WT revealed low levels of staining in all
brain regions in the absence of injury. Representative ex-
amples are shown in Figure 2E,F. There was no significant
difference ( p< 0.05) in Iba-1 immunostaining (number of
Iba-1 positive cells per 200high-power field) in sham A1AR
KO versus WT in any region (Table 3). In addition, Iba-1
levels were 3- to 10-fold higher in injured mice than in cor-
responding shams, in every brain region, which reflected the
anticipated low baseline level of Iba-1 immunoreactivity (Ito
et al., 2001).
Fluoro-Jade C positive neurons were not detected in any
brain section in either CA1 or CA3 hippocampus at this mild
injury level at 24 h after CCI in either A1AR KO or WT mice
(data not shown). Cortical volumes at 7 days after injury did
not differ between A1AR KO and WT in either the injured or
contralateral hemispheres (Fig. 3), a finding that was observed
regardless of whether the analysis was based on overt tissue
loss or abnormal tissue staining (see Methods section). Com-
parison of percent differences between contralateral and ipsi-
lateral cortical volumes indicated that this mild injury level
resulted in loss of *7% of the cortex in the hemisphere ipsi-
lateral to injury. Percent differences between contralateral and
ipsilateral cortical volumes also did not differ between KO and
WT. Representative examples of cresyl violet staining of brain
sections in A1AR KO and WT are shown in Figure 2G, H.
In BV-2 cells the highly selective A1AR agonist CCPA
inhibited 3H-thymidine incorporation in a concentration-
dependent manner (Fig. 4). Although the highly selective
FIG. 2. Representative images of Iba-1 and cresyl violet stained brain sections. (A) A1-receptor (A1AR) knockout (KO)
ipsilateral cortex—Iba-1, post-traumatic brain injury (TBI). (B) Wild-type (WT) ipsilateral cortex—Iba-1, post-TBI. (C) A1AR
KO ipsilateral thalamus—Iba-1, post-TBI. (D) WT ipsilateral thalamus—Iba-1, post-TBI. (E) A1AR KO ipsilateral cortex—Iba-
1, naı¨ve. (F) WT ipsilateral cortex—Iba-1, naı¨ve. (G) A1AR KO—cresyl violet, post-TBI. (H) WT—cresyl violet, post-TBI. Iba-1
staining demonstrates a significant and diffuse increase in the microglial response to TBI in A1AR KO versus WT mice (A–F).
In contrast, no obvious difference in lesion volume is appreciated between A1AR KO and WT mice (G, H). (I) Sampling for
quantification of Iba-1 immunostaining.
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A2AAR agonist CGS and the highly selective A3AR agonist
Cl-IB-MECA also caused concentration-related decreases in
3H-thymidine incorporation by BV-2 cells, these compounds
were less potent in this regard compared with CCPA (Fig. 4).
NECA, a compound that activates A1ARs, A2AARs, A2BArs,
and A3ARs, was even more potent as an inhibitor of BV-2
proliferation thanwasCCPA, CGS, or CL-IB-MECA (Fig. 4). 2-
CADO (1mM), a non-selective activator of A1ARs, A2AARs,
A2BArs, and A3ARs, also profoundly inhibited
3H-thymidine
incorporation by BV-2 cells (Fig. 5), and this response was re-
versed partially by DPCPX (100nM; A1AR selective antago-
nist), SCH (100 nM; A2AAR selective antagonist), MRS
(100 nM; A2BAR selective antagonist), and VUF (100 nM;
A3AR selective antagonist) (Fig. 5). Combined, the antagonists
completely reversed the inhibitory effects of 2-chlor-
oadenosine (Fig. 5). As shown in Figure 6, mRNA for all four
adenosine receptorswas detected in BV-2 cells in the following
order of abundance: A2BARs>A2AARs&A3ARs>A1ARs.
Discussion
Our results provide three lines of evidence that A1AR ac-
tivation serves as an important brake on the microglial re-
sponse to TBI: (1) at 7 days after CCI, Iba-1 immunostaining is
enhanced in the A1AR KO in most brain regions; (2) in mouse
microglial culture, proliferation, as assessed by 3H-thymidine
incorporation, is inhibited by CCPA, a highly-selective A1AR
agonist; and (3) in mouse microglial culture, inhibition of
proliferation by the non-selective adenosine receptor agonist
2-CADO is partially reversed by DPCPX, a highly-selective
A1AR antagonist.
Two prior studies in CNS inflammation models have
shown increases in microglial proliferation in A1AR KO ver-
sus WT mice (Synowitz et al., 2006; Tsutsui et al., 2004). In
EAE, A1AR KO mice have enhanced microglial proliferation
that is accompanied by increased damage and proin-
flammatory gene expression in spinal cord. Synowitz and
associates (2006) report increased microglial proliferation
after implantation of glioblastoma tumor cells in A1AR KO vs
WT. Thus, A1AR activation may attenuate the microglial
response across insults. Tsutsui and colleagues (2004) also
report that bone marrow-derived macrophages from A1AR
KO mice show enhanced proinflammatory gene expression
after LPS stimulation. Macrophages also accumulate in brain
after CCI (Bayir et al., 2005; Foley et al., 2009; Tong et al.,
2002). The role of the A1AR in regulating themicroglial versus
macrophage response in TBI remains to be defined.
Si and associates (1996) report inhibition of phorbol-
stimulated proliferation of rat microglia by nonselective and
A1AR-specific agonists. However, the effects of A1AR acti-
vation on microglial proliferation in culture are complex.
Gebicke-Haerter and associates (1996) report that simulta-
neous administration of A1AR and A2AR agonists elicited
microglial proliferation rather than its inhibition in un-
stimulated rat microglia while Wollmer and associates (2001)
report no effect of the A1AR agonist CPA on proliferation of
unstimulated rat microglia. It is likely necessary to stimulate
proliferation in order to observe inhibition of proliferation
with AR agonists.
Table 3. Microglia as Assessed by Iba-1
Immunostaining in Sham A1AR KO and WT Mice
Brain structure A1AR KO WT P value
b
CA1 29.00 6.66a 24.67 4.06 0.61
CA3 24.00 9.64 14.67 3.84 0.42
Cortex 37.67 10.37 21.00 3.51 0.20
Thalamus 23.33 10.84 12.00 4.04 0.38
A1AR, adenosine A1 receptor; KO, knockout; WT, wild type.
aMean SEM.
bComparison between genotypes by two-tailed t-test; n¼ 3 per
genotype.
FIG. 3. Cortical volume at 7 days after traumatic brain injury (TBI) did not differ significantly between A1-receptor (A1AR)
knockout (KO) (=, n¼ 18; 9 male, 9 female) versus wild-type (WT) (þ=þ, n¼ 17; 9 male, 8 female) mice in either the
injured or contralateral hemispheres, regardless of quantification method used (see Methods section).
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Our cell culture findings suggest that A1ARs inhibit mi-
croglial proliferation, as indicated by the potent effects of
CCPA and DPCPX. Nonetheless, other adenosine receptor
subtypes also inhibit proliferation. Although the effects of the
A2AAR and A3AR are modest, the A2BAR potently inhibits
growth as indicated by (1) large effects of the non-selective
adenosine receptor agonist NECA and (2) reversal of the ef-
fects of 2-CADO by the selective A2BAR antagonist MRS.
Thus, it would be of interest to study microglial proliferation
after TBI in A2BAR KO mice.
The roles of the various adenosine receptor subtypes likely
depend on their relative expression. In BV-2 cells, despite the
fact that the expression of A1ARmRNA is*1=10th that of the
A2AAR and A3AR and 1=100th that of the A2BAR, the A1AR
FIG. 4. The effects of adenosine receptor agonists on 3H-thymidine incorporation in BV-2 cells. BV-2 cells were treated for
24 h with the indicated concentrations of one of four different agonists and pulsed with 3H-thymidine during the last 4 h of
incubation. The graph shows 3H-thymidine incorporation normalized to a well (basal) on the same culture plate that received
no treatment. Statistical analyses were performed on absolute 3H-thymidine incorporation. The overall p value for the effect
of each agonist by analysis of variance was p< 0.000001. P values are for multiple comparisons tests compared with basal.
Values are means and SEMs for n¼ 6.
FIG. 5. The effects of the non-selective adenosine receptor agonist 2-CADO (1mM) on 3H-thymidine incorporation in BV-2
cells in the absence (vehicle) and presence of selective adenosine receptor antagonists (either DPCPX, SCH, MRS, or VUF; all
at 0.1 mM). BV-2 cells were treated for 24 h without or with 2-CADO and without or with the indicated antagonists and pulsed
with 3H-thymidine during the last 4 h of incubation. The graph shows the effects of 2-CADO on 3H-thymidine incorporation
normalized to a well (basal) on the same culture plate that was not treated with 2-CADO but did receive either the vehicle for
the antagonists or one of the antagonists. The antagonists per se did not alter basal 3H-thymidine incorporation. Statistical
analyses were performed on percent of basal, and the overall p value for the effect of the antagonists by analysis of variance
was p< 0.000001. ap< 0.05 compared with vehicle (multiple comparisons tests). Values are means and SEMs for n¼ 6.
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makes a major contribution to the inhibitory effects of 2-
CADO. A1ARs are thus potent inhibitors of microglial pro-
liferation because of their high affinity. It is conceivable that
immortalization of microglia to generate the BV-2 cell line
suppresses A1AR expression. It would be important to de-
termine the relative roles of adenosine receptors in cell pro-
liferation of primary microglia.
We are surprised to observe that the enhanced microglial
response is seen in brain structures ipsilateral and contralat-
eral to the injury, although the response is greater ipsilateral to
the injury. This supports the work of Hall and associates
(2005, 2008) who report bilateral fiber degeneration after CCI
in mice. The global microglial response in A1AR KO mice
suggests that even after a mild CCI with no hippocampal
neuronal death, a low level of diffuse fiber degeneration may
represent the stimulus for this response; further studies are
needed.
Given the exacerbation of damage observed by Fedele and
co-workers (2006) in A1AR KOmice treated with kainate, it is
surprising that we do not observe greater neuropathological
injury in KO versus WT mice. However, we cannot com-
pletely rule out the possibility that A1AR KOmice could have
increased damage after CCI. Varma and associates (2002),
using a much more severe injury level than in the current
study, showed that parenchymal injection of the selective
A1AR agonist CCPA after CCI in mice reduced neuronal
death, but only in CA3. The important role of A1AR in hip-
pocampus may make that region more amenable to A1AR
agonist or antagonist treatment than the cortex (Gime´mez-
Llort et al., 2005; Gundlfinger et al., 2007). Fedele and asso-
ciates (2006) noted exacerbation of damage after kainate
injection in A1AR KO mice in hippocampus. Since seizures
and hippocampal excitation are linked after TBI (Golarai et al.,
2001), and that seizures exacerbate anoxia-induced neuronal
death in hippocampus (Dzhala et al., 2000), it may be difficult
to establish an injury level producing sufficient vulnerability
in CA1 or CA3 without precipitating status epileptics and
death in the A1AR KO. Even using this very mild CCI, 31%
delayed mortality is seen in A1AR KO versus 0% in WT.
Nevertheless, we do not detect FJCþneurons. Another
strategy to define the role of A1ARs in CCI would be to use a
more severe injury and treatmicewith an anti-convulsant.We
cannot rule out a compensatory effect of A1AR deficiency, as
suggested by Olsson and colleagues (2004), who report that
CA1 neuronal death after brain ischemia is not increased in
the A1AR KO.
Although there is a body of support for a deleterious role of
microglia in brain injury (Lai and Todd, 2006), a beneficial role
is also possible and may depend on the insult, timing, and
other factors. Lalancette-He´bert and colleagues (2007)
showed the neuroprotective potential of microglia in focal
cerebral ischemia. It is tempting to speculate that the en-
hanced microglial proliferation in A1AR KO is neuroprotec-
tive and accounts for the lack of increased neuronal damage
versus WT.
Tsutsui and co-workers (2004) show that chronic treatment
with the non-selective A1AR antagonist caffeine upregulates
A1AR on microglia and abrogates damage in EAE. Li and
colleagues (2008) report that chronic, but not acute, treatment
with caffeine attenuates brain edema and leukocyte influx in
mice after TBI. These findings take on greater significance
given the recent report of an association between increased
levels of caffeine in cerebrospinal fluid and favorable out-
comes in humans after TBI (Sachse et al., 2008). Thus, the
potential benefit of caffeine in TBI may be mediated by anti-
inflammatory effects of A1AR upregulation. Given the ubiq-
uitous nature of caffeine use (Strong et al., 2000), further study
is warranted.
There are several limitations of this work. Microglial pro-
liferation, activation, and migration are regulated differen-
tially (Hanisch and Kettenmann, 2007), and we did not
distinguish between them in our in vivowork. Upregulation of
Iba-1 could contribute to our in vivo findings. Also, we did not
define the contributions ofmicroglia versusmacrophages.We
did not characterize a complete time course, although 7 days
after TBI is a good target for proof-of-concept. Iba-1 is only
FIG. 6. mRNA expression for adenosine receptor subtypes using quantitative real-time PCR. Left panel is for A1, A2A, and
A3 receptor mRNA (scale 0–0.0005) and right panel is for A2B receptor mRNA (scale 0–0.005). Threshold cycle (Ct) for target
mRNA was subtracted from the Ct for b-actin mRNA to calculate DCt, and relative mRNA levels were expressed as 2DCt as
recommended by Varma and Cheng (2008). The overall p value from analysis of variance was p< 0.000001. P values in graph
are for multiple comparisons tests. Values are means and SEMs for n¼ 9.
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one of many microglial markers that could be used. Finally,
we cannot rule out a possible role for non-convulsive seizures
or status epilepticus in mediating both the microgial response
(Avignone et al., 2008) and mortality after mild CCI. Lai and
Todd (2006) report that glutamate can stimulate microglial
proliferation, and we cannot rule out glutamate release in
mediating this process.
We conclude A1AR KO mice exhibit an enhanced micro-
glial response after CCI, although neuronal damage was
not increased. A1AR activation may represent an endoge-
nous inhibitor of microglial proliferation and possibly a new
therapeutic avenue to manipulate this aspect of neuro-
inflammation in TBI.
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